Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways

Leukemia

Volumn 24, Issue 6, 2010, Pages 1216-1220

  Kohlmann, A ^a   Bullinger, L ^b   Thiede, C ^c   Schaich, M ^c   Schnittger, S ^a   Dohner K ^b   Dugas, M ^d   Klein, H U ^d   Dohner H ^b   Ehninger, G ^c   Haferlach, T ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FICOLL; FLT3 LIGAND; MOLECULAR MARKER; NUCLEOPHOSMIN; CCAAT ENHANCER BINDING PROTEIN; CD135 ANTIGEN; CEBPA PROTEIN, HUMAN; FLT3 PROTEIN, HUMAN; MESSENGER RNA; NUCLEAR PROTEIN; TUMOR MARKER;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; ALGORITHM; ALLELE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CHROMOSOME BANDING PATTERN; CYTOGENETICS; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; KARYOTYPE; LETTER; MICROARRAY ANALYSIS; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; SENSITIVITY ANALYSIS; CLASSIFICATION; DNA MICROARRAY; GENETICS; KARYOTYPING; METABOLISM; MUTATION; PREDICTION AND FORECASTING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CCAAT-ENHANCER-BINDING PROTEINS; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION PROFILING; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77954569665     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.73     Document Type: Letter

References (19)

1. Haferlach T. Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2008; 2008: 400-411.
2. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918. (Pubitemid 351620111)
3. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66. (Pubitemid 35177429)
4. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733-3739. (Pubitemid 41739006)
5. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335. (Pubitemid 34627197)
6. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011-4020. (Pubitemid 43726809)
7. Kohlmann A, Kipps TJ, Rassenti LZ, Downing JR, Shurtleff SA, Mills KI et al. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Br J Haematol 2008; 142: 802-807.
8. Kohlmann A, Haschke-Becher E, Wimmer B, Huber-Wechselberger A, Meyer-Monard S, Huxol H et al. Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH study. Clin Chem 2008; 54: 1705-1715.
9. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266. (Pubitemid 40110814)
10. Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stemcell maintenance. Blood 2005; 106: 899-902. (Pubitemid 41076430)
11. Verhaak RG, Goudswaard CS, van PW, Bijl MA, Sanders MA, Hugens W et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106: 3747-3754. (Pubitemid 41739008)
12. The Gene Ontology project in 2008. Nucleic Acids Res 2008; 36: D440-D444.
13. Efron B, Tibshirani R. On testing the significance of sets of genes. Ann Appl Stat 2007; 1: 107-129.
14. Wouters BJ, Jorda MA, Keeshan K, Louwers I, Erpelinck-Verschueren CA, Tielemans D et al. Distinct gene expressio profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007; 110: 3706-3714. (Pubitemid 350159640)
15. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009; 113: 3088-3091.
16. Bullinger L, Dohner K, Kranz R, Stirner C, Frohling S, Scholl C et al. An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 2008; 111: 4490-4495.
17. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 2009; 94: 131-134.
18. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn IARC: Lyon, France, 2008.
19. Ioannidis JP, Allison DB, Ball CA, Coulibaly I, Cui X, Culhane AC et al. Repeatability of published microarray gene expression analyses. Nat Genet 2009; 41: 149-155.